Evidence suggests that the expression level of PDL1 in tumors may indicate the potential for clinical benefit, resulting in the approval of pembrolizumab as a first-line treatment for patients with recurrent or metastatic HNSCC in 2019 [53]. Here, CD274 is linked to head and neck squamous cell carcinoma.